Brookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

Equities research analysts at Brookline Capital Management initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a note issued to investors on Wednesday,Benzinga reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. Brookline Capital Management’s price objective would indicate a potential upside of 389.13% from the company’s current price.

A number of other analysts have also issued reports on the stock. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Rodman & Renshaw initiated coverage on shares of Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Maxim Group initiated coverage on Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Quince Therapeutics currently has an average rating of “Buy” and a consensus target price of $8.67.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $1.84 on Wednesday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The business has a 50 day moving average price of $1.55 and a two-hundred day moving average price of $1.01. The firm has a market cap of $80.96 million, a PE ratio of -1.48 and a beta of 0.74.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC boosted its holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 339,125 shares of the company’s stock after acquiring an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.